{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".662","upperLimit":".928","value":".795"},{"groupId":"OG001","lowerLimit":".662","upperLimit":".928","value":".784"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Overall survival was analyzed from the time of registration to the date of death or last known date living. Due to median OS time not being reached due to lack of deaths at the time of this report by either arm, the 2 year OS rate has been reported. This analysis censors living patients at 2 years.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.","id":"OG000","title":"Phase II Arm I (Pomalidomide, Dexamethasone)"},{"description":"Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Survival (OS) (Phase II)","type":"SECONDARY","unitOfMeasure":"proportion of patients alive"}